drugset
Drugs / Autologous effector lymphocytes expanded ex-vivo
last change Nov 2019 re-read 3 minutes ago

Autologous effector lymphocytes expanded ex-vivo

Cell therapy

Developed for
follicular lymphoma
Investigated by
Clinica Universidad de Navarra, Universidad de Navarra · Spanish National Health System

Trials 1

today NCT01329354 · Ph 2
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01329354 Mar 2011 → Nov 2019 follicular lymphoma Clinica Universidad de Navarra, Universidad de Navarra Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Autologous effector lymphocytes expanded ex-vivo ClinicalTrials.gov intervention name — accepted as the source's own label NCT01329354 ↗
Action Deplete “LAK cells generated from FL patients induce cytotoxicity against tumor cell lines.” PMID 26659089 ↗ Apr 2016
Modality Cell therapy “The intervention consists on the administration of autologous effector lymphocytes expanded ex-vivo every two Rituximab administrations.” NCT01329354 ↗